期刊文献+

微小病变型肾病综合征患儿肾组织HS结构分析

Expression of Glomerular Heparan Sulfate Domains in Pediatric Patients with Minimal Change Nephrotic Syndrome
下载PDF
导出
摘要 目的探讨微小病变型肾病综合征(minimal change nephritic syndrome,MCNS)患儿肾脏组织硫酸乙酰肝素(heparan sulfate,HS)结构特点。方法应用4种分别识别不同HS结构的抗-HS单克隆抗体:10E4、J M403、Hepss1和3G10,对13例MCNS患儿肾脏活检组织和5例正常肾组织进行间接免疫荧光染色,分析不同HS位点表达变化,同时用ELISA法测定MCNS患儿在活检时尿液HS浓度。结果MCNS极期患儿肾脏10E4、J M403和Hepss1表达IOD值分别为42.89±14.90、30.13±8.10和38.67±10.68,均较正常肾组织(50.16±9.14、35.55±7.01和47.58±10.03)降低(P<0.05),MCNS缓解期患儿肾脏Hepss1表达(38.26±8.83)较正常组降低,J M403肾脏表达(43.21±6.78)却较正常组升高,10E4表达变化无统计学意义,MCNS激素依赖组患儿10E4、J M403和Hepss1与正常对照组差异均无统计学意义;在3组MCNS患儿3G10肾组织表达与正常组相比无明显变化。MC-NS患儿尿液HS浓度(257.17±52.27)μg/mL较正常对照组(172.77±54.50)μg/mL增高(P<0.01)。结论肾脏HS丢失可能与MCNS蛋白尿发生有关;而肾脏HS丢失原因可能是由于MCNS患儿肾脏HS结构异于常人,比较容易与呼吸道病毒发生结合,从而直接和/或间接导致肾脏HS表达降低。 Objectives To investigate the expression of glomerular heparin sulfate (HS) in paediatric patients with minimal change nephritic syndrome (MCNS). Methods The kidyney tissues were collected by biopsy from 13 paediatric patients with MCNS, while 5 normal renal biopsy samples were used as control. HS in glomeruli was analysed by indirect immunofluoreseence staining using four different monoelonal antibodies, Hepss1, 3G10, JM403 and 10E4, which all recognize distinct HS species and each interacts with a specific HS domain. The concentrations of urine heparan sulfate also were measured by enzyme-linked immunosorbent assay (Elisa). Results Expression of HS fine domains was aberrant in paediatric patients compared with control subjects. Children with MCNS in replase showed a decreased glomerular expression of 10E4, JM403 and Hepssl (P〈0. 05). The level of urinary HS was significantly increased in peadiatric patients with MCNS when compared with that in control subjects (P〈0.01). Conclusion These results suggest that loss of heparan sulphate in renal tissue may play a role in the pathogenesis of MCNS proteinuria.
出处 《四川大学学报(医学版)》 CAS CSCD 北大核心 2009年第1期55-58,共4页 Journal of Sichuan University(Medical Sciences)
关键词 微小病变型肾病综合征 硫酸乙酰肝素 Minimal change nephrotic syndrome (MCNS) Heparan sulfate
  • 相关文献

参考文献8

  • 1Esko JD, Lindahl U. Molecular diversity of heparan sulfate. J Clin Invest, 2001 ; 108(2) : 169-173.
  • 2Lindahl U, Kusche-Gullberg M, Kjellen L. Regulated diversity of heparan sulfate. J Biol Chem, 1998 ; 273(39) : 24979-24982.
  • 3van den Born J, Pisa B, Bakker MA, et al. No change in glomerular heparan sulfate structure in early human and experimental diabetic nephropathy. J Biol Chem, 2006, 281 (40): 29606-29613.
  • 4Oguma T, Tomatsu S, Montano AM, et al. Analytical method for the determination of disaccharides derived from keratan, heparan, and dermatan sulfates in human serum and plasma by high-performance liquid chromatography/turbo ionspray ionization tandem mass spectrometry. Anal Biochem, 2007,368 (1) : 79-86.
  • 5Celie JW, Keuning ED, Beelen RH, et al. Identification of Lselectin binding heparan sulfates attached to collagen type ⅩⅦ. J Biol Chem,2005,280(29) :26965-26973.
  • 6Branten AJ, van den Born J, Jansen JL, et al. Familial nephropathy differing from minimal change nephropathy and focal glomeruloselerosis. Kidney Int,2001,59(2) :693-701.
  • 7Yokoyama H, Sato K, Okudaira M, et al. Serum and urinary concentrations of heparan sulfate in patients with diabetic nephropathy. Kidney Int,1999,56(2) :650-658.
  • 8Nakayama K, Natori Y, Sato T, et al. Altered expression of NDST-1 messenger RNA in puromycin aminonucleoside nephrosis. J Lab Clin Med,2004;143(2):106-114.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部